133 related articles for article (PubMed ID: 22469839)
1. Downregulation of cylindromatosis gene, CYLD, confers a growth advantage on malignant melanoma cells while negatively regulating their migration activity.
Ishikawa Y; Tsunoda K; Shibazaki M; Takahashi K; Akasaka T; Masuda T; Maesawa C
Int J Oncol; 2012 Jul; 41(1):53-60. PubMed ID: 22469839
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
3. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.
Wickström SA; Masoumi KC; Khochbin S; Fässler R; Massoumi R
EMBO J; 2010 Jan; 29(1):131-44. PubMed ID: 19893491
[TBL] [Abstract][Full Text] [Related]
4. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling.
Massoumi R; Chmielarska K; Hennecke K; Pfeifer A; Fässler R
Cell; 2006 May; 125(4):665-77. PubMed ID: 16713561
[TBL] [Abstract][Full Text] [Related]
5. miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells.
Dynoodt P; Speeckaert R; De Wever O; Chevolet I; Brochez L; Lambert J; Van Gele M
Int J Oncol; 2013 Apr; 42(4):1443-51. PubMed ID: 23404256
[TBL] [Abstract][Full Text] [Related]
6. CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and β1-integrin signaling pathways.
Ke H; Augustine CK; Gandham VD; Jin JY; Tyler DS; Akiyama SK; Hall RP; Zhang JY
J Invest Dermatol; 2013 Jan; 133(1):221-9. PubMed ID: 22832488
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met.
Yan D; Zhou X; Chen X; Hu DN; Dong XD; Wang J; Lu F; Tu L; Qu J
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1559-65. PubMed ID: 19029026
[TBL] [Abstract][Full Text] [Related]
8. Cadherin-7 interacts with melanoma inhibitory activity protein and negatively modulates melanoma cell migration.
Winklmeier A; Contreras-Shannon V; Arndt S; Melle C; Bosserhoff AK
Cancer Sci; 2009 Feb; 100(2):261-8. PubMed ID: 19200257
[TBL] [Abstract][Full Text] [Related]
9. p54nrb is a new regulator of progression of malignant melanoma.
Schiffner S; Zimara N; Schmid R; Bosserhoff AK
Carcinogenesis; 2011 Aug; 32(8):1176-82. PubMed ID: 21642354
[TBL] [Abstract][Full Text] [Related]
10. An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells.
Alameda JP; Moreno-Maldonado R; Navarro M; Bravo A; Ramírez A; Page A; Jorcano JL; Fernández-Aceñero MJ; Casanova ML
Oncogene; 2010 Dec; 29(50):6522-32. PubMed ID: 20838385
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of CYLD in human colon and hepatocellular carcinomas.
Hellerbrand C; Bumes E; Bataille F; Dietmaier W; Massoumi R; Bosserhoff AK
Carcinogenesis; 2007 Jan; 28(1):21-7. PubMed ID: 16774947
[TBL] [Abstract][Full Text] [Related]
12. Status of RASSF1A in uveal melanocytes and melanoma cells.
Calipel A; Abonnet V; Nicole O; Mascarelli F; Coupland SE; Damato B; Mouriaux F
Mol Cancer Res; 2011 Sep; 9(9):1187-98. PubMed ID: 21788308
[TBL] [Abstract][Full Text] [Related]
13. Tumour suppressor CYLD is a negative regulator of the mitotic kinase Aurora-B.
Sun L; Gao J; Huo L; Sun X; Shi X; Liu M; Li D; Zhang C; Zhou J
J Pathol; 2010 Aug; 221(4):425-32. PubMed ID: 20593489
[TBL] [Abstract][Full Text] [Related]
14. Nucleus accumbens-associated 1 contributes to cortactin deacetylation and augments the migration of melanoma cells.
Tsunoda K; Oikawa H; Tada H; Tatemichi Y; Muraoka S; Miura S; Shibazaki M; Maeda F; Takahashi K; Akasaka T; Masuda T; Maesawa C
J Invest Dermatol; 2011 Aug; 131(8):1710-9. PubMed ID: 21562571
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma.
Massoumi R; Kuphal S; Hellerbrand C; Haas B; Wild P; Spruss T; Pfeifer A; Fässler R; Bosserhoff AK
J Exp Med; 2009 Jan; 206(1):221-32. PubMed ID: 19124656
[TBL] [Abstract][Full Text] [Related]
16. PAX4 has the potential to function as a tumor suppressor in human melanoma.
Hata S; Hamada J; Maeda K; Murai T; Tada M; Furukawa H; Tsutsumida A; Saito A; Yamamoto Y; Moriuchi T
Int J Oncol; 2008 Nov; 33(5):1065-71. PubMed ID: 18949370
[TBL] [Abstract][Full Text] [Related]
17. Loss of CYLD might be associated with development of salivary gland tumors.
Fukuda M; Hiroi M; Suzuki S; Ohmori Y; Sakashita H
Oncol Rep; 2008 Jun; 19(6):1421-7. PubMed ID: 18497946
[TBL] [Abstract][Full Text] [Related]
18. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
19. RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis.
Oh JJ; Taschereau EO; Koegel AK; Ginther CL; Rotow JK; Isfahani KZ; Slamon DJ
Lung Cancer; 2010 Dec; 70(3):253-62. PubMed ID: 20338664
[TBL] [Abstract][Full Text] [Related]
20. RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb.
Wang J; Hua W; Huang SK; Fan K; Takeshima L; Mao Y; Hoon DS
Oncotarget; 2015 Oct; 6(30):30165-77. PubMed ID: 26334503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
